Showing 1961-1970 of 2152 results for "".
- Biotech Healthcare Announces Korean Good and Manufacturing Practices Approvalhttps://modernod.com/news/biotech-healthcare-announces-korean-good-and-manufacturing-practices-approval/2476544/Biotech Healthcare has received KGMP (Korean Goods & Manufacturing Practice) approval, allowing its ophthalmic products to be accessible to South Korean markets. “Today when we talk about addressing the urgent need of global eye care problems, may that be cataracts or the myopic wave t
- Alcon Forms Strategic Alliance to Bring Image-Guided Biometry to the Cataract Refractive Suitehttps://modernod.com/news/alcon-forms-strategic-alliance-to-bring-image-guided-biometry-to-the-cataract-refractive-suite/2476535/Alcon announced a strategic alliance with MOVU to bring an image-guided biometer to global markets. Based in Santa Clara, California, MOVU, a Santec company, is the manufacturer of the ARGOS Swept Source Optical Coherence Tomography (SS-OCT) biometer used to measure eye parameters for patients be
- Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the UShttps://modernod.com/news/santen-and-glaukos-enter-into-collaboration-and-distribution-agreement-for-exclusive-distribution-of-the-microshunt-de-128-in-the-us/2476507/Santen Pharmaceutical announced that its US subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt in the U.S. market. Financial
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Topcon Introduces the IS-100 Ophthalmic Unithttps://modernod.com/news/topcon-introduces-the-is-100-ophthalmic-unit/2476366/Topcon Medical Systems has announced the launch of the new IS-100 Ophthalmic Unit to the export market. The IS-100 will replace the existing IS-600N model which has been discontinued, and includes several new features that simplifies the installation, enhances its durability and facilitates its u
- EMA Handed Down Fewer Positive Drug Opinions in 2018https://modernod.com/news/ema-handed-down-fewer-positive-drug-opinions-in-2018/2476203/In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017, according to a report in Medscape. The 84 medicines given a thumbs up by EMA’s Committee for Medicin
- Imprimis Pharmaceuticals Changes Name to Harrow Healthhttps://modernod.com/news/imprimis-pharmaceuticals-changes-name-to-harrow-health/2476233/Imprimis Pharmaceuticals announced it has formally changed its name to Harrow Health and began trading as “HROW” on the NASDAQ Capital Markets on January 2, 2019. “Our new name reflects our business model of c
- EyePoint Pharmaceuticals Added to NASDAQhttps://modernod.com/news/eyepoint-pharmaceuticals-added-to-nasdaq/2479607/EyePoint Pharmaceuticals announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). EyePoint’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the perform
- Ophthalmic Investment Funds Led by Retinal Gene Therapy Developershttps://modernod.com/news/ophthalmic-investment-funds-led-by-retinal-gene-therapy-developers/2476147/Ophthalmology remains one of the most active areas of medical technology investment, attracting monies from venture capitalists, public markets, large ophthalmic companies, and private equity. Market Scope just published its 2017/2018 Ophthalmic Deals Book, analyzing recent ophthalmic fund